Literature DB >> 27094151

New imidazoquinoxaline derivatives: Synthesis, biological evaluation on melanoma, effect on tubulin polymerization and structure-activity relationships.

Zahraa Zghaib1, Jean-François Guichou2, Johanna Vappiani3, Nicole Bec4, Kamel Hadj-Kaddour3, Laure-Anaïs Vincent3, Stéphanie Paniagua-Gayraud3, Christian Larroque4, Georges Moarbess5, Pierre Cuq3, Issam Kassab5, Carine Deleuze-Masquéfa6, Mona Diab-Assaf5, Pierre-Antoine Bonnet3.   

Abstract

Microtubules are considered as important targets of anticancer therapy. EAPB0503 and its structural imidazo[1,2-a]quinoxaline derivatives are major microtubule-interfering agents with potent anticancer activity. In this study, the synthesis of several new derivatives of EAPB0503 is described, and the anticancer efficacy of 13 novel derivatives on A375 human melanoma cell line is reported. All new compounds show significant antiproliferative activity with IC50 in the range of 0.077-122μM against human melanoma cell line (A375). Direct inhibition of tubulin polymerization assay in vitro is also assessed. Results show that compounds 6b, 6e, 6g, and EAPB0503 highly inhibit tubulin polymerization with percentages of inhibition of 99%, 98%, 90%, and 84% respectively. Structure-activity relationship studies within the series are also discussed in line with molecular docking studies into the colchicine-binding site of tubulin.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiproliferative activity; Human melanoma cancer cell line (A375); Imidazo[1,2-a]quinoxaline; Molecular docking; Structure–activity relationship; Tubulin depolymerization

Mesh:

Substances:

Year:  2016        PMID: 27094151     DOI: 10.1016/j.bmc.2016.04.004

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  11 in total

1.  Fluorescence Study of Imidazoquinoxalines.

Authors:  Cindy Patinote; Kamel Hadj-Kaddour; Marjorie Damian; Carine Deleuze-Masquéfa; Pierre Cuq; Pierre-Antoine Bonnet
Journal:  J Fluoresc       Date:  2017-05-03       Impact factor: 2.217

2.  Luminescent bis(benzo[d]thiazolyl)quinoxaline: facile synthesis, nucleic acid and protein BSA interaction, live-cell imaging, biopharmaceutical research and cancer theranostic application.

Authors:  Lavanya Thilak Babu; Gajanan Raosaheb Jadhav; Priyankar Paira
Journal:  RSC Adv       Date:  2019-03-18       Impact factor: 4.036

3.  Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechanisms in correlation with cytotoxicity.

Authors:  Alexis Courbet; Nicole Bec; Caroline Constant; Christian Larroque; Martine Pugniere; Safia El Messaoudi; Zahraa Zghaib; Sonia Khier; Carine Deleuze-Masquefa; Florence Gattacceca
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

4.  Imidazo[1,2-a]quinoxalines Derivatives Grafted with Amino Acids: Synthesis and Evaluation on A375 Melanoma Cells.

Authors:  Adrien Chouchou; Cindy Patinote; Pierre Cuq; Pierre-Antoine Bonnet; Carine Deleuze-Masquéfa
Journal:  Molecules       Date:  2018-11-15       Impact factor: 4.411

5.  Synthesis and Evaluation of New Quinoxaline Derivatives of Dehydroabietic Acid as Potential Antitumor Agents.

Authors:  Wen Gu; Shuang Wang; Xiaoyan Jin; Yaliang Zhang; Dawei Hua; Tingting Miao; Xubing Tao; Shifa Wang
Journal:  Molecules       Date:  2017-07-11       Impact factor: 4.411

6.  EAPB0503: An Imiquimod analog with potent in vitro activity against cutaneous leishmaniasis caused by Leishmania major and Leishmania tropica.

Authors:  Rana El Hajj; Hanady Bou Youness; Laurence Lachaud; Patrick Bastien; Carine Masquefa; Pierre-Antoine Bonnet; Hiba El Hajj; Ibrahim Khalifeh
Journal:  PLoS Negl Trop Dis       Date:  2018-11-21

7.  Synthesis and Properties of Quinoxaline-Containing Benzoxazines and Polybenzoxazines.

Authors:  Chien Han Chen; Tsung Yen Yu; Jen-Hao Wu; Mathivathanan Ariraman; Tzong-Yuan Juang; Mahdi M Abu-Omar; Ching-Hsuan Lin
Journal:  ACS Omega       Date:  2019-05-23

8.  EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AML.

Authors:  Hala Skayneh; Batoul Jishi; Rita Hleihel; Maguy Hamie; Rana El Hajj; Carine Deleuze-Masquefa; Pierre-Antoine Bonnet; Marwan El Sabban; Hiba El Hajj
Journal:  Int J Mol Sci       Date:  2022-03-22       Impact factor: 5.923

Review 9.  Recent advances in the transition-metal-free synthesis of quinoxalines.

Authors:  Biplob Borah; L Raju Chowhan
Journal:  RSC Adv       Date:  2021-11-19       Impact factor: 4.036

10.  Lipid nanocapsules formulation and cellular activities evaluation of a promising anticancer agent: EAPB0503.

Authors:  Adrien Chouchou; Anne Aubert-Pouëssel; Christophe Dorandeu; Zahraa Zghaib; Pierre Cuq; Jean-Marie Devoisselle; Pierre-Antoine Bonnet; Sylvie Bégu; Carine Deleuze-Masquefa
Journal:  Int J Pharm Investig       Date:  2017 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.